Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause
Primary Purpose
Menopause, Nutritional Intervention, Bone Diseases
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Placebo Comparator
Zinc Supplement
Magnesium supplement
Sponsored by
About this trial
This is an interventional treatment trial for Menopause focused on measuring Menopuase, Zinc, Magnesium, Antioxidant, Bone loss, Nutritional intervention
Eligibility Criteria
Inclusion Criteria:
- to present postmenopausal status (with at least 12 months of amenorrhea)
- to present low status in Mg and/or Zn obtained in a previous biochemical assessment
- not present any pathology that could affect their nutritional status
- not to be subjected to hormone replacement therapy (HRT)
- not to demonstrate lactose intolerance
Exclusion criteria
- acute or terminal illness
- unwillingness to either complete the study requirements or to be randomised into control or experimental group
- to be smoker
- to be on a medication regimen
Sites / Locations
- Universidad de Granada
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
Placebo Supplemented Group
Magnesium Supplemented Group
Zinc Supplemented Group
Arm Description
Placebo control
Magnesium Group
Zinc Group
Outcomes
Primary Outcome Measures
Antioxidant status
Total antioxidant capacity (TAC) determination in plasma samples was carried out evaluating the reduction power of Cu2+ from the action of antioxidants present in samples (TAC kit, Jaica, Shizuoka, Japan). Values were expressed in umol/L.
Oxidative stress
Glutathione peroxidase (GPx) in mU/mL and Superoxide dismutase (SOD) in U/mL. GPx activity was determined by using the Bioxytech GPx-340™ kit (OxisResearch™), an indirect colorimetric assay of the activity of c-GPx [28]. SOD activity was determined by using the Randox Ransod kit (RANDOX Laboratories Ltd., United Kingdom).
Secondary Outcome Measures
Anthropometric assessment - Height
Values were expressed in centimeters.
Anthropometric assessment - Waist circumference
Values were expressed in centimeters.
Anthropometric assessment - Body composition by bioelectrical impedance
Body composition assessment was taken by multifrequency bioelectrical impedance (Tanita MC-980 Body Composition Analyzer MA Multifrequency Segmental, Barcelona, Spain). The analyzer complies with the applicable European standards (93/42EEC, 90/384EEC) for use in the medical industry. Participants were informed in advance of the required conditions prior to the measurement: no alcohol less than 24 hours before the measurement, no vigorous exercise less than 12 hours prior to the measurement, no food or drink less than 3 hours prior to the measurement, and no urination immediately before the measurement. All measurements were taken simultaneously during the morning in fasting conditions. The following measurements were taken: weight, body mass index (calculated as weight/height^2 and expressed kg/m2) and fat mass (expressed in kilograms and as the percentage of body fat), fat free mass (expressed in kilograms and as the percentage of fat free mass), muscle mass (expressed in kilograms).
Intake assessment
Dietary intake was performed at baseline and after two months of intervention. Nutritional assessment was quantitatively and qualitatively performed using a 72 hours' dietary record and food frequency questionnaire (FFQ). Data from food intakes were obtained in the course of individual interviews to request information from each participant about the types of foods and serving sizes. Dietary intake was compared with the daily recommended allowances (DRA). Insufficient intake levels were determined by comparing actual intakes of different nutrients with the recommended intake for each participant and were recorded as below 75% of the RDA. FFQ was used to set the information about the frequency consumption in each group of foods. FFQ was compared with the recommendations proposed by the Spanish Community Nutrition Society (SENC) and expressed as the percentage of participants below or above the recommended servings.
Biochemical parameters - Clinical-nutritional parameters
Biochemistry was performed after 12 hours of fasting first thing in the morning, by specialists puncturing the cubital vena cava (Venoject®). The following measurements were taken: Glucose (mg/dL), creatinine (mg/dL), urea (mg/dL), uric acid (mg/dL), triglycerides (mg/dL), total cholesterol (mg/dL), total proteins (g/dL), transferrin (mg/dL) and albumin (mg/dL).
Hormonal parameters
Hormonal parameters were performed after 12 hours of fasting first thing in the morning, by specialists puncturing the cubital vena cava (Venoject®) and determined by colorimetric enzymoimmunoassay techniques (ECLIA, Elecsys 2010 and Modular Analytics E170, Roche Diagnostics, Mannheim, Germany.
The following measurements were taken: leptin (ng/mL), PTH (pg/mL) and Osteocalcin (pg/mL).
Full Information
NCT ID
NCT03672513
First Posted
September 8, 2018
Last Updated
September 13, 2018
Sponsor
Universidad de Granada
1. Study Identification
Unique Protocol Identification Number
NCT03672513
Brief Title
Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause
Official Title
Short-term Supplementation, Bone Turnover and Antioxidant Status in Postmenopausal Stage: A Placebo Controlled Study.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
September 8, 2016 (Actual)
Primary Completion Date
November 1, 2017 (Actual)
Study Completion Date
September 8, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad de Granada
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a 8-week, double-blinded, placebo-controlled, randomized intervention trial to investigate the effects of Mg and Zn supplementation on antioxidant status and bone hormonal parameters. Participants were randomly assigned to one of three treatment groups: Placebo group (PbG: 25 women); Magnesium Group - 500 mg/day of Mg (MgG: 27 women); Zinc Group - 50 mg/day of Zn (ZnG: 26 women).
Detailed Description
Seventy-eight healthy postmenopausal volunteers aged between 44 and 76 were recruited once had been informed about the protocol. This is a 8-week, double-blinded, placebo-controlled, randomized intervention trial to investigate the effects of Mg and Zn supplementation on antioxidant status and bone hormonal parameters. Participants were randomly assigned to one of three treatment groups: Placebo group (PbG: 25 women); Magnesium Group - 500 mg/day of Mg (MgG: 27 women); Zinc Group - 50 mg/day of Zn (ZnG: 26 women).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Menopause, Nutritional Intervention, Bone Diseases
Keywords
Menopuase, Zinc, Magnesium, Antioxidant, Bone loss, Nutritional intervention
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
78 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo Supplemented Group
Arm Type
Placebo Comparator
Arm Description
Placebo control
Arm Title
Magnesium Supplemented Group
Arm Type
Experimental
Arm Description
Magnesium Group
Arm Title
Zinc Supplemented Group
Arm Type
Experimental
Arm Description
Zinc Group
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Comparator
Intervention Description
Oral administration of 1 daily capsule containing lactose
Intervention Type
Dietary Supplement
Intervention Name(s)
Zinc Supplement
Intervention Description
Oral administration of 1 daily capsule containing 50 mg/day of Zn
Intervention Type
Dietary Supplement
Intervention Name(s)
Magnesium supplement
Intervention Description
Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
Primary Outcome Measure Information:
Title
Antioxidant status
Description
Total antioxidant capacity (TAC) determination in plasma samples was carried out evaluating the reduction power of Cu2+ from the action of antioxidants present in samples (TAC kit, Jaica, Shizuoka, Japan). Values were expressed in umol/L.
Time Frame
2 months
Title
Oxidative stress
Description
Glutathione peroxidase (GPx) in mU/mL and Superoxide dismutase (SOD) in U/mL. GPx activity was determined by using the Bioxytech GPx-340™ kit (OxisResearch™), an indirect colorimetric assay of the activity of c-GPx [28]. SOD activity was determined by using the Randox Ransod kit (RANDOX Laboratories Ltd., United Kingdom).
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Anthropometric assessment - Height
Description
Values were expressed in centimeters.
Time Frame
2 months
Title
Anthropometric assessment - Waist circumference
Description
Values were expressed in centimeters.
Time Frame
2 months
Title
Anthropometric assessment - Body composition by bioelectrical impedance
Description
Body composition assessment was taken by multifrequency bioelectrical impedance (Tanita MC-980 Body Composition Analyzer MA Multifrequency Segmental, Barcelona, Spain). The analyzer complies with the applicable European standards (93/42EEC, 90/384EEC) for use in the medical industry. Participants were informed in advance of the required conditions prior to the measurement: no alcohol less than 24 hours before the measurement, no vigorous exercise less than 12 hours prior to the measurement, no food or drink less than 3 hours prior to the measurement, and no urination immediately before the measurement. All measurements were taken simultaneously during the morning in fasting conditions. The following measurements were taken: weight, body mass index (calculated as weight/height^2 and expressed kg/m2) and fat mass (expressed in kilograms and as the percentage of body fat), fat free mass (expressed in kilograms and as the percentage of fat free mass), muscle mass (expressed in kilograms).
Time Frame
2 months
Title
Intake assessment
Description
Dietary intake was performed at baseline and after two months of intervention. Nutritional assessment was quantitatively and qualitatively performed using a 72 hours' dietary record and food frequency questionnaire (FFQ). Data from food intakes were obtained in the course of individual interviews to request information from each participant about the types of foods and serving sizes. Dietary intake was compared with the daily recommended allowances (DRA). Insufficient intake levels were determined by comparing actual intakes of different nutrients with the recommended intake for each participant and were recorded as below 75% of the RDA. FFQ was used to set the information about the frequency consumption in each group of foods. FFQ was compared with the recommendations proposed by the Spanish Community Nutrition Society (SENC) and expressed as the percentage of participants below or above the recommended servings.
Time Frame
2 months
Title
Biochemical parameters - Clinical-nutritional parameters
Description
Biochemistry was performed after 12 hours of fasting first thing in the morning, by specialists puncturing the cubital vena cava (Venoject®). The following measurements were taken: Glucose (mg/dL), creatinine (mg/dL), urea (mg/dL), uric acid (mg/dL), triglycerides (mg/dL), total cholesterol (mg/dL), total proteins (g/dL), transferrin (mg/dL) and albumin (mg/dL).
Time Frame
2 months
Title
Hormonal parameters
Description
Hormonal parameters were performed after 12 hours of fasting first thing in the morning, by specialists puncturing the cubital vena cava (Venoject®) and determined by colorimetric enzymoimmunoassay techniques (ECLIA, Elecsys 2010 and Modular Analytics E170, Roche Diagnostics, Mannheim, Germany.
The following measurements were taken: leptin (ng/mL), PTH (pg/mL) and Osteocalcin (pg/mL).
Time Frame
2 months
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female, Adult
Minimum Age & Unit of Time
44 Years
Maximum Age & Unit of Time
76 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
to present postmenopausal status (with at least 12 months of amenorrhea)
to present low status in Mg and/or Zn obtained in a previous biochemical assessment
not present any pathology that could affect their nutritional status
not to be subjected to hormone replacement therapy (HRT)
not to demonstrate lactose intolerance
Exclusion criteria
acute or terminal illness
unwillingness to either complete the study requirements or to be randomised into control or experimental group
to be smoker
to be on a medication regimen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elena Planells, PhD
Organizational Affiliation
Universidad de Granada
Official's Role
Study Director
Facility Information:
Facility Name
Universidad de Granada
City
Granada
ZIP/Postal Code
18071
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35278643
Citation
Vazquez-Lorente H, Molina-Lopez J, Herrera-Quintana L, Gamarra-Morales Y, Quintero-Osso B, Lopez-Gonzalez B, Planells E. Erythrocyte Zn concentration and antioxidant response after supplementation with Zn in a postmenopausal population. A double-blind randomized trial. Exp Gerontol. 2022 Jun 1;162:111766. doi: 10.1016/j.exger.2022.111766. Epub 2022 Mar 9.
Results Reference
derived
Learn more about this trial
Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause
We'll reach out to this number within 24 hrs